Hypertension and diabetes: Role of the renin-angiotensin system

被引:42
作者
Jandeleit-Dahm, Karin [1 ]
Cooper, Mark E. [1 ]
机构
[1] Baker Heart Res Inst, Danielle Mem Ctr Diabet Complicat, Melbourne, Vic 3004, Australia
关键词
D O I
10.1016/j.ecl.2006.06.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hypertension is often associated clinically with diabetes as part of the insulin-resistance syndrome or as a manifestation of renal disease. Elevated systemic blood pressure accelerates micro- and macrovascular complications in diabetes. Vasoactive hormone pathways including the renin-angiotensin-aldosterone system (RAAS) appear to play a pivotal role in the pathogenesis and progression of diabetic complications and possibly of diabetes itself. Recent studies have increased our understanding of the complexity of the RAAS with identification of new components of this cascade including angiotensin-converting enzyme 2 and a putative renin receptor. Agents that interrupt the RAAS confer end-organ protection in diabetes via hemodynamic and non-hemodynamic mechanisms. Trials are investigating the possible role of RAAS blockade in the prevention of type 2 diabetes.
引用
收藏
页码:469 / +
页数:23
相关论文
共 113 条
[81]   Renoprotective effects of adding angootensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy - A randomized double-blind crossover trial [J].
Rossing, K ;
Jacobsen, P ;
Pietraszek, L ;
Parving, HH .
DIABETES CARE, 2003, 26 (08) :2268-2274
[82]   Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy - A randomized, double-masked, cross-over study [J].
Rossing, K ;
Schjoedt, KJ ;
Smidt, UM ;
Boomsma, F ;
Parving, HH .
DIABETES CARE, 2005, 28 (09) :2106-2112
[83]   Dual blockade of the renin-angiotensin system in diabetic nephropathy - A randomized double-blind crossover study [J].
Rossing, K ;
Jensen, BR ;
Christensen, PK ;
Parving, HH .
DIABETES CARE, 2002, 25 (01) :95-100
[84]   Preventing microalbuminuria in type 2 diabetes [J].
Ruggenenti, P ;
Fassi, A ;
Ilieva, AP ;
Bruno, S ;
Iliev, IP ;
Brusegan, V ;
Rubis, N ;
Gherardi, G ;
Arnoldi, F ;
Ganeva, M ;
Ene-Iordache, B ;
Gaspari, F ;
Perna, A ;
Bossi, A ;
Trevisan, R ;
Dodesini, AR ;
Remuzzi, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (19) :1941-1951
[85]  
Schjoedt KJ, 2005, DIABETOLOGIA, V48, pA6
[86]   Beneficial effect of lisinopril plus telinisartan in patients with type 2 diabetes, microalbuminuria and hypertension [J].
Sengul, AM ;
Altuntas, Y ;
Kürklü, A ;
Aydin, L .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 71 (02) :210-219
[87]  
Sjolie AK, 2002, J RENIN-ANGIO-ALDO S, V3, P255
[88]   Diabetes, hypertension, and cardiovascular disease - An update [J].
Sowers, JR ;
Epstein, M ;
Frohlich, ED .
HYPERTENSION, 2001, 37 (04) :1053-1059
[89]  
Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
[90]  
Steffes MW, 2003, JAMA-J AM MED ASSOC, V290, P2159, DOI 10.1001/jama.290.16.2159